Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Accu-Break Pharmaceuticals was a specialty pharmaceutical company that developed a proprietary drug delivery platform focused on 'splittable' tablet technology. The company's Accu-Break designs, including Accu-B and Accu-T, allowed tablets to be broken into precise, smaller doses without crumbling, which is particularly useful for medications requiring dose titration. This technology was designed to improve patient compliance and safety by ensuring accurate dosing when a full tablet is not required. Accu-Break primarily operated by licensing its technology to other pharmaceutical companies, such as Aurobindo Pharma, for use in both branded and generic medications. The company's portfolio included applications in cardiovascular health and other therapeutic areas where flexible dosing is critical. Accu-Break Pharmaceuticals and its subsidiary, Accu-Break Generics, are currently inactive, having dissolved their business operations in the mid-2010s.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ACCU-BREAK Generics.